Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 27NIH 3INDUSTRY 3NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Multiple Myeloma 19Lymphoma 3Neoplasms, Plasma Cell 2Smoldering Multiple Myeloma 1Sezary Syndrome 1Myelodysplastic Syndromes 1Mycosis Fungoides 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Leukemia, Myeloid, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hematologic Neoplasms 1

Interventions

Cytarabine 30Daunorubicin 15Gene Expression Profiling 9Gemtuzumab 9Flow Cytometry 9Idarubicin 8Mitoxantrone 7sargramostim 6fludarabine 6Polymerase Chain Reaction 6Methotrexate 6Filgrastim 6Etoposide 6Cyclophosphamide 6Busulfan 6fludarabine phosphate 5Specimen Handling 5merphos 4Whole-Body Irradiation 4Stem Cell Transplantation 4Peripheral Blood Stem Cell Transplantation 4Mycophenolic Acid 4Biopsy 4Tacrolimus 3Observation 3Melphalan 3Immunologic Techniques 3Hydrocortisone 3DNA Methylation 3Clofarabine 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Leukemia, Myeloid, Acute × Lenalidomide × Clear all
NCT01556477 2012-03-16

The Efficacy of Azacitidine +/- Lenalidomide in High-risk Myelodysplastic Syndrome (MDS)and Acute Myeloid Leukemia (AML) With Del(5q).

Nordic MDS Group

Phase 2 Unknown
72 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡